Welcome to the Horizon 2020 atherosclerosis research program website
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into
AMC Researchers Siroon Bekkering and Simone Verweij both awarded Best Presentor at the Lipoprotein(a) Satellite Meeting (From Bench to Bedside) in Innsbruck (2016). The AMC department of Vascular Medicine (Erik Stroes) is imbedded in the department of Internal Medicine, and has a strong focus on translational research aimed at pathophysiology, diagnosis and treatment of atherosclerotic
BACKGROUND AND AIMS: We have recently reported that monocytes can undergo functional and transcriptional reprogramming towards a long-term pro-inflammatory phenotype after brief in vitro exposure to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and is mediated by epigenetic remodeling and a metabolic switch towards increased aerobic glycolysis. We hypothesize that
BACKGROUND: Innate immune memory or ‘trained immunity’ has recently been described as an important property of cells of the innate immune system. Due to the increased interest in this important new field of immunological investigation we sought to determine the optimal conditions for an in-vitro experimental protocol of monocyte training using three of the most
Diabetes strongly predisposes to cardiovascular disease (CVD), the leading cause of mortality in these patients, as well as in the entire population. Hyperglycemia is an important cardiovascular risk factor as shown by the observation that even transient periods of hyperglycemia, despite return to normoglycemia during follow-up, increase the risk for CVD, a phenomenon termed ‘hyperglycemic
BLUEPRINT was officially launched on 1 October 2011. With the principal funding of €30 million by the European Union the project has been the European cornerstone of the international research cooperation effort International Human Epigenome Consortium, bringing together organisations and researchers from across the globe. Involving 42 leading European universities, research institutes, small and medium-sized
In this translational work, we provide evidence in support of the concept that pro inflammatory oxidized phospholipids are major contributors to the atherogenicity of Lipoprotein(a) [Lp(a)] by showing that (1) subjects with elevated Lp(a) have increased arterial inflammation in vivo, (2) monocytes isolated from subjects with elevated Lp(a) remain in a long-lasting activated state ex
Prof. dr. Mihai Netea, full partner in REPROGRAM, was awarded the Spinoza Prize 2016, the highest award in Dutch science. Every year, the Netherlands Organisation for Scientific Research (NWO) awards the Spinoza Prize. The winners were announced by NWO chairman Jos Engelen on Friday 10 June. The NWO Spinoza Prize is both an award and
Prof. Matthias Nahrendorf (Harvard Medical School), a key-partner within the REPROGRAM in collaboration with Prof. Filip K. Swirski published a scientific article in the European Heart Journal (Impact factor 15.2) on a topic highly related to REPROGRAM. You will find his article here .
On February 1 2016, the project members of REPROGRAM gathered at Schiphol Amsterdam airport for the official Kick-off meeting. After an inspiring introduction by the Prof. Dr. Erik Stroes (Project Coordinator) a crash course in Epigenetic Reprogramming was provided by Siroon Bekkering (Postdoctoral Researcher, AMC). With this encouraging launch in our minds, presentations per work
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.